AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
Preprint
Abstract
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and treat COVID-19, and reduce the risk of severe disease and death. Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct non-overlapping epitopes on the spike protein receptor binding domain to potently neutralize SARS-CoV-2. Initially isolated from individuals with prior SARS-CoV-2 infection, the two mAbs were designed to extend their half-lives and abrogate effector functions. The AZD7442 mAbs individually prevent the spike protein from binding to angiotensin-converting enzyme 2 receptor, blocking virus cell entry. Together, these two mAbs create a higher barrier to viral escape and a wider breadth of coverage, neutralizing all known SARS-CoV-2 variants of concern. In a non-human primate model of SARS-CoV-2 infection, prophylactic AZD7442 administration prevented infection, while therapeutic administration accelerated virus clearance from lung. In an ongoing Phase I study in healthy participants ( NCT04507256 ), 300 mg intramuscular AZD7442 provided SARS-CoV-2 serum geometric mean neutralizing titers >10-fold above those of convalescent sera for ≥3 months, which remained 3-fold above those of convalescent sera 9 months post-AZD7442 administration. Approximately 1–2% of serum AZD7442 levels were detected in nasal mucosa, a site of SARS-CoV-2 infection. Extrapolation of the time course of serum AZD7442 concentrations suggests AZD7442 may provide up to 12 months of protection and benefit individuals at high-risk of COVID-19.Keywords
All Related Versions
- Published version: Science Translational Medicine, 14 (635), eabl8124.
This publication has 49 references indexed in Scilit:
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCNew England Journal of Medicine, 2018
- Comparing Hydrogen Deuterium Exchange and Fast Photochemical Oxidation of Proteins: a Structural Characterisation of Wild-Type and ΔN6 β2-MicroglobulinJournal of the American Society for Mass Spectrometry, 2018
- Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm InfantsThe Pediatric Infectious Disease Journal, 2018
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsScience Translational Medicine, 2017
- Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2017
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2013
- Structural characterization of a human Fc fragment engineered for lack of effector functionsActa Crystallographica Section D Structural Biology, 2008
- Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)Journal of Biological Chemistry, 2006
- Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysisVirology Journal, 2005
- Antibody Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2004